StockWireNews

Time's Up: Low Float Nasdaq Breakout Idea (MIRA) Has A 3 Must-See Potential Catalysts (Strong Analyst Target)

$22.70 Zacks SCR Analyst Target - Full Report

December 4th

Greetings Readers,

Let's go...

Trading on the Nasdaq Capital Market, we've uncovered a potential wrecking ball.

With a low float of fewer than 9Mn shares, volatility could end up being an explosive catalyst to watch for closely.

Speaking of potential volatility, it was quite recently that this profile rocketed short term. We're talking around 250+% in under a week...

Could another big move be right around the corner?

One analyst seems to think it's possible.

Recently updating and upgrading his target to $22.70, this Nasdaq breakout idea may just hold a crazy amount of upside potential from its closing valuation Friday.

Like 450+% potential upside...

But this might be the most important bit of info to focus on right now.

This company is on the disruptor forefront and could soon be ready to take on these TAM battles:

With these two TAM's up for grabs, this little-known company might not fly under the radar for much longer as human trials will be ramping up in 2024 for their next generation T-H-C analog.

Drop everything right now and pull up:

MIRA Pharmaceuticals, Inc. (MIRA)

MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company developing an unscheduled novel synthetic T-H-C analog.

This novel compound is currently under investigation for potentially treating adults suffering from anxiety and cognitive decline, often associated with early-stage dementia.

Developing The Next Generation FDA Approved Novel Synthetic T-H-C Analog

MIRA Pharmaceuticals, Inc. is a life sciences company focused on the development of MIRA1a, a novel synthetic T-H-C analog.

MIRA1a is being developed to treat anxiety and cognitive decline in the elderly and neuropathic pain without impurities or the negative side effects associated with cann-a-bis ("CB") plant extracts.

MIRA1a is classified as an unscheduled drug by the U.S. Drug Enforcement Administration (DEA).

Market Opp. - Summary of U.S. Epidemiology

The eligible patient pool analysis for MIRA1a highlights a potential large patient pool looking for potential treatments to their conditions

U.S. Le.gal MJ Market

Initial dual path focus: Potentially winning in traditional markets and the T-H-C analog markets using a safe, effective and FDA-approved treatment option.

Therapeutic Focus Areas

MIRA1a is under evaluation for three key therapeutic areas with high disease burden and significant unmet needs:

Neuropathic Pain

Neuropathic Pain is a complex pain condition that arises from dysfunction or damage to the nervous system. It is a pain state that can continue even when the initial cause of the pain, such as an injury or disease, has healed or been treated. It represents a malfunction in the nerve's signaling rather than a response to continued harm.

Affecting approximately 7-10% of the general population. Examples include diabetic peripheral neuropathy, postherpetic neuralgia, and multiple sclerosis related neuropathy.

Existing treatments may involve medications like anticonvulsants, which can reduce the excitability of nerves, thereby dampening abnormal electrical activity, or antidepressants, which increase serotonin and norepinephrine levels that modulate the way the brain perceives pain. However, their effectiveness can be limited, and they might carry side effects. Opiates are used less frequently due to addiction risks.

Developing targeted and efficient therapies for neuropathic pain stands as a priority for numerous pharmaceutical companies to address this common source of suffering and morbidity for treatment-resistant cases. Innovative strategies, including cann-a-binoid therapies, are under exploration to tackle the distinctive challenges posed by this type of pain.

Anxiety and Cognitive Decline in the Elderly

Anxiety disorders are chronic conditions marked by an excessive & persistent sense of apprehension, with physical symptoms such as sweating, palpitations, and feelings of stress.

~40 million U.S. adults have an anxiety disorder, including phobias, Social Anxiety Disorder, PTSD, Generalized Anxiety Disorder, and Panic Disorder.

Standard treatment leverages cognitive-behavioral therapy, though pharmacological options include. SSRIs, SNRIs, and TCAs.

Cognitive Impairment

Cognitive Impairment encompasses conditions marked by notable decline in one's cognitive abilities including Alzheimer's disease and dementia.

~16 million people in the US are living with cognitive impairment.

Current treatments for cognitive impairment do not temporarily restore lost function and are only capable of delaying the progression of the disease.

Anticipated Timeline

Pre-clinical work is underway and expected to be completed by Q1’24.

Positioning MIRA for an initial IND filing in Q3 2024.

Grab Key Sources Here: Company Website. Company Presentation.

-----

The Top 3 Potential Catalysts To Focus On Right Now!

#1. MIRA is a low float profile (volatility will need to be on watch.)

As of Friday's closing bell, Yahoo Finance was reporting MIRA to have a float of 8.84Mn shares.

Why is this important? One word: Volatility.

When a profile has a float this small, volatility can create an environment for explosive intraday and short term chart moves.

One thing that can influence such a move is company news (whether good or bad).

In fact, it could be why MIRA was able to move over $4.00+ short term recently...

-----

#2. Zacks SCR analyst target of $22.70 starts making headlines.

Last week, Zacks Small-Cap Research analyst, Brad Sorensen, updated a research report on MIRA.

In it, he highlights why MIRA has a $22.70 price target which suggests over 450% potential upside from its closing valuation Friday.

Here's a key highlight:

• Adding to its continuing pursuit of the company’s primary treatment, MIRA1, MIRA announced that it has acquired an exclusive license to develop and commercialize a product commonly known as Ketamir, which, in layman’s terms, is a potential derivative of the antidepressant ket-a-mine that has shown indications of having fewer side effects, working more rapidly, and having the opp. to impact millions of patients that have not responded to other, existing treatments. The terms of the deal appear to us to be fashioned in a way that is low risk for MIRA with the potential for a very high return.
  

-----

#3. Last week's major news announcement could provide an incredible breakout spark near term.

Check it out:

New Data from IQVIA Supports Potential $3Bn Annual Market

"This positive financial outlook bolsters our confidence in advancing Ketamir-2's clinical development," said Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals. "We are poised to make a significant impact to a market that urgently needs innovative solutions."

Annupama Kumar, MBBS, Vice President of Drug Development at MIRA Pharmaceuticals, added: "Oral delivery of Ketamir-2 could transform depression management, offering more consistent and accessible treatment for patients. This advancement is not just a milestone for MIRA Pharmaceuticals, but a beacon of hope for millions battling severe depression."

Read the full article here.

-----

Coverage is officially initiated on MIRA Pharmaceuticals, Inc. (MIRA).

When updates pop up this week, I'll get them out to you quickly.

Talk soon,

Kai Parker

StockWireNews

(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)